FY2025 EPS Estimate for Arvinas Increased by Analyst

Arvinas, Inc. (NASDAQ:ARVN) – Stock analysts at Leerink Partnrs raised their FY2025 EPS estimates for shares of Arvinas in a research note issued to investors on Wednesday, November 5th. Leerink Partnrs analyst A. Berens now anticipates that the company will earn ($0.16) per share for the year, up from their prior estimate of ($0.72). The consensus estimate for Arvinas’ current full-year earnings is ($3.81) per share. Leerink Partnrs also issued estimates for Arvinas’ Q4 2025 earnings at $0.02 EPS, FY2026 earnings at ($1.51) EPS and FY2027 earnings at ($1.59) EPS.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.27. Arvinas had a negative net margin of 18.73% and a negative return on equity of 9.77%. The business had revenue of $41.90 million during the quarter, compared to analyst estimates of $29.36 million. During the same quarter in the previous year, the business posted ($0.68) EPS. Arvinas’s quarterly revenue was down 59.1% on a year-over-year basis.

Other equities analysts have also issued research reports about the stock. Wells Fargo & Company reduced their price target on shares of Arvinas from $16.00 to $15.00 and set an “overweight” rating for the company in a research report on Thursday, November 6th. Stephens boosted their target price on shares of Arvinas from $14.00 to $15.00 and gave the company an “overweight” rating in a research note on Monday. Weiss Ratings reissued a “sell (e+)” rating on shares of Arvinas in a research report on Wednesday, October 8th. Guggenheim decreased their price target on shares of Arvinas from $16.00 to $15.00 and set a “buy” rating for the company in a research note on Thursday, August 7th. Finally, Barclays upped their price objective on Arvinas from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. Eleven investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Arvinas has a consensus rating of “Hold” and a consensus price target of $16.39.

Arvinas Price Performance

Shares of NASDAQ ARVN opened at $11.21 on Monday. The company has a 50-day moving average price of $8.96 and a 200-day moving average price of $7.93. The stock has a market capitalization of $719.91 million, a P/E ratio of -13.84 and a beta of 2.38. Arvinas has a 1 year low of $5.90 and a 1 year high of $27.76.

Hedge Funds Weigh In On Arvinas

Institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in Arvinas by 18.4% in the first quarter. Vanguard Group Inc. now owns 8,362,200 shares of the company’s stock worth $58,703,000 after acquiring an additional 1,299,639 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in Arvinas during the first quarter valued at about $80,000. Monaco Asset Management SAM lifted its stake in Arvinas by 185.6% during the second quarter. Monaco Asset Management SAM now owns 900,936 shares of the company’s stock worth $6,631,000 after purchasing an additional 585,477 shares during the last quarter. Palumbo Wealth Management LLC purchased a new position in shares of Arvinas in the 2nd quarter worth about $492,000. Finally, Federated Hermes Inc. boosted its holdings in shares of Arvinas by 1,965.0% in the 1st quarter. Federated Hermes Inc. now owns 980,674 shares of the company’s stock worth $6,884,000 after purchasing an additional 933,183 shares in the last quarter. 95.19% of the stock is currently owned by institutional investors.

Insider Transactions at Arvinas

In related news, Director Briggs Morrison bought 30,000 shares of the business’s stock in a transaction on Monday, September 22nd. The stock was acquired at an average price of $7.57 per share, for a total transaction of $227,100.00. Following the purchase, the director directly owned 76,021 shares in the company, valued at $575,478.97. This trade represents a 65.19% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 4.73% of the company’s stock.

Arvinas declared that its Board of Directors has authorized a share buyback plan on Wednesday, September 17th that permits the company to buyback $100.00 million in outstanding shares. This buyback authorization permits the company to repurchase up to 17.9% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s management believes its stock is undervalued.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.